Skip to main content
SpringerLink
Log in

Avosentan stopped in it’s ascent to diabetic nephropathies

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Speedel.Speedel Stops Current Spp301 Phase III Trial in Diabetic Kidney Disease in the Interests of Patient Safety. Media Release: 19 Dec 2006. Available from: URL: http://www.speedel.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Avosentan stopped in it’s ascent to diabetic nephropathies. React. Wkly. 1134, 2 (2007). https://doi.org/10.2165/00128415-200711340-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711340-00005

Keywords

Search

Navigation